BioPharma Resources

Drug Trial Radar · NCT05922345

Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.

A Multicenter, Randomized, Double-blind, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of AL2846 Capsules Combined With TQB2450 Injection Compared With Docetaxel Injection in Patients With Advanced Non-small Cell Lung Cancer Who Have Failed With Immunotherapy.

Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 518 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

518

Planned (sponsor's estimate)

Start

Jun 8, 2023

Primary completion

Aug 2025

Study completion Dec 2025

Sponsor

Sponsor type
Industry
First posted
Jun 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the efficacy of AL2846 capsules in combination with TQB2450 injection or Docetaxel injection in patients with advanced NSCLC who have previously failed immune checkpoint inhibitors (anti-PD-1 monoclonal antibody, anti-PD-L1 monoclonal antibody), regardless of new anti-tumor treatment and early termination of treatment.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • TQB2450 injection, docetaxel injection matching placebo, AL2846 capsulesDrug

    AL2846 capsules is a multi-targeted small molecule receptor tyrosine kinase inhibitor. TQB2450 Injection is an anti-programmed death-1 (PD-L1).

  • TQB2450 placebo, docetaxel injection, AL2846 matching placeboDrug

    Docetaxel injection is a type of chemotherapy for treatment of different types of cancer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: From randomization to the time of death from any cause, assessed up to 36 months.

Locations

71 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Not yet recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Tiantan Hospital Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Chest Hospital Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Three Gorges Hospital Affiliated to Chongqing University

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Fujian Provincial Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Not yet recruiting

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China · Not yet recruiting

  • Gansu Provincial Cancer Hospital

    Lanzhou, Gansu, China · Not yet recruiting

  • Meizhou People's Hospital

    Meizhou, Guangdong, China · Not yet recruiting

  • Cancer Hospital of Shantou University Medical College

    Shantou, Guangdong, China · Not yet recruiting

  • Zhongshan City People's Hospital

    Zhongshan, Guangdong, China · Not yet recruiting

  • Guigang people's hospital

    Guigang, Guangxi, China · Not yet recruiting

  • Liuzhou people's hospital

    Liuzhou, Guangxi, China · Not yet recruiting

  • Guangxi Medical University Afiliated Tomor Hospital

    Nanning, Guangxi, China · Not yet recruiting

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, China · Not yet recruiting

  • The Second Affiliated Hospital of Zunyi Medical University

    Zunyi, Guizhou, China · Not yet recruiting

  • The Second Affiliated Hospital of Hainan Medical College

    Haikou, Hainan, China · Not yet recruiting

  • Hainan Provincial People's Hospital

    Haikou, Hainan, China · Not yet recruiting

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China · Not yet recruiting

  • Affiliated Hospital of Chengde Medical College

    Chengde, Hebei, China · Not yet recruiting

  • Tangshan People's Hospital

    Tangshan, Hebei, China · Not yet recruiting

  • Daqing Oilfield General Hospital

    Daqing, Heilongjiang, China · Not yet recruiting

  • Affiliated Cancer Hospital of Harbin Medical University

    Harbin, Heilongjiang, China · Not yet recruiting

  • Jiamusi Tuberculosis Hospital (Jiamusi Cancer Hospital)

    Jiamusi, Heilongjiang, China · Not yet recruiting

  • Tong Ji Hospital Affiliated To Tongji Medical College HUST

    Wuhan, Hubei, China · Not yet recruiting

  • Hubei Cancer Hospital (HBCH)

    Wuhan, Hubei, China · Not yet recruiting

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China · Not yet recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • The Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China · Not yet recruiting

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.